Kornimate/medical-research-clean huggingface dataset:
tablet-based application for cognitive therapy

Conditions: Brain Injuries

Summary: cognitive impairments such as deficits in attention, executive functions, perception, language, speech, arithmetics, and memory are very common symptoms after acquired brain injury, which can be caused by neurological diseases such as stroke, cerebral haemorrhage or traumatic brain injury. around 83% of patients with brain injury suffer from a sequelae of cognitive impairments. since the effects caused by neurological diseases can vary greatly from person to person, intensive and individual neuro-rehabilitation is necessary to help patients return to an independent life in the best possible way. in the dach area (i.e., in germany, austria, and switzerland), patients with cognitive impairments following brain injuries generally receive this intensive and interdisciplinary treatment while being hospitalised in an inpatient clinic following acute medical care. however, once they leave inpatient care facilities, there are insufficient treatment options readily available to them due to limitations/shortages in the healthcare system's resources, although studies indicate that an increase in therapy time (both in outpatient settings at home or in care facilities) enables greater, long-term rehabilitation progress and faster reintegration and participation in everyday life. thanks to recent technical advancements, digital treatment options now promise the availability of sufficiently frequent and intensive treatment outside of clinic settings. in that context, the myreha therapy software (available as an app on ios ad android tablets), a certified medical device, was developed to enable patients to receive individualised and intensive therapy regardless of the healthcare system's constraints. to test the effectiveness of the myreha therapy software, in this two-arm, randomised, controlled study, patients in the intervention group receive treatment through the myreha therapy software in addition to their usual standard care (i.e., care-as-usual - cau), while the control group only receives cau. treatment outcomes (i.e., rehabilitation progress) are measured based on the cerad-plus.


Eligibility criteria:
inclusion criteria: * cognitive impairment (deficits in attention, arithmetics, executive functions, memory, language, perception) according to cerad-plus after a diagnosed brain injury ≥ 4 weeks ago * no prior experience with a therapy app for neurological deficits * motivation to use the therapy software regularly * sufficiently good german language skills prior to the brain injury exclusion criteria: * being unable to use a tablet without assistance * severe visual or hearing impairment that interferes with the performance on psychometric testing procedures * any pre-existing speech or language disorder or dementia prior to the onset of brain injury * an ongoing outpatient or inpatient rehabilitation at the time of study inclusion or planned rehabilitation of the primary disease during the study period * serious disabling disease(s) which, in the opinion of the investigator, would preclude participation in the study until the follow-up phase * pregnancy
monitoring pulmonary artery pressure by implantable device responding to ultrasonic signal

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate and document appropriate clinical safety and performance of the remon chf implantable pressure sensor including the corresponding delivery system, the remon chf home unit, the remon chf clinic system devices and associated application software. it is a small clinical trial to determine the feasibility of the device. the primary outcome measure relates to feasibility and not to health outcomes.

this study was a prospective feasibility, non-randomised, singlearm, multi-centre, interventional clinical investigation performed at 4 international sites. patients were implanted with the remon chf implantable pressure sensor utilizing the corresponding delivering system. measurements were taken with the remon chf home unit and the remon chf clinic system. follow-up visits took place at one, three and six months after implant. per protocol, a minimum of 30 patients was required to demonstrate safety of the device. the study was conducted in accordance with iso 14155:2003 (parts i and ii), the declaration of helsinki and all applicable local and national regulations in the countries of submission.

Eligibility criteria:
inclusion criteria: * patients who exhibit signs and symptoms of nyha class iii or iv heart failure. * patients who are able to visit the clinic frequently during the 6 months following implantation. * patients who are willing and able to perform all follow-up procedures. exclusion criteria: 1. patients under the age of 18 2. pregnant women or women that plan to get pregnant during the study. 3. patients with, tricuspid or pulmonic stenosis, pulmonary stents, right sided mechanical heart valves 4. contraindication to antiplatelet therapy (aspirin and clopidogrel) 5. patients suffering from active infection (on antibiotic therapy) 6. known intracardiac mass (right atrial or right ventricular) 7. patients who have been implanted with a vad 8. patients who are candidates for listing for heart transplantation if it is deemed that they have a possibility of receiving a heart within the next 6 months 9. patients that have lead implanted at the heart right side of the heart within the last 6 months 10. patients with any terminal illness, or with a life expectancy of less than 6 months 11. patients that are unable to lie flat for the duration of the procedure 12. patients that are unable to operate the home unit (due to physical or mental constrain) 13. patients after pneumonectomy 14. patients treated with oral anticoagulants inr \> 1.5 prior to catheterization 15. patients with severe chronic renal failure (creatinine \> 2.5 mg/dl) 16. patients suffered from acute myocardial infarction within the three months prior the study 17. patients that underwent open heart surgery within 4 weeks prior the study.
calorie restriction and changes in body composition, disease, function, and quality of life in older adults

Conditions: Obesity; Diabetes; Hypertension; Hyperlipidemia

Summary: the investigators want to determine if the benefits of weight loss outweigh the potential risk in a group of older adults. the investigators will test the hypothesis that changes in diet composition alone or in conjunction with weight loss will have a significant effect on fat stores, and as a result, improve cardiometabolic risk factors and functional status in adults 65 and older.


Eligibility criteria:
inclusion criteria: * at least 65 years of age * bmi 27 - 42 kg/m2 - at increased health risk (taking at least 1 medication for hypertension, hyperlipidemia, or type 2 diabetes) exclusion criteria: * difficulties chewing or swallowing food * digestive diseases that may affect the ability to follow a high fiber diet * cognitive impairment * depression * recent weight change (+/- 10 lbs in the last 12 months) * poorly controlled blood pressure * history of non-skin cancer in last 5 years * cardiovascular disease event in past 6 months or severe pulmonary disease or renal failure * major liver dysfunction * current smoker or quit less than months prior * history of prior surgical procedures for weight control or liposuction * use of estrogen or testosterone replacement therapy * current use of insulin or sulfonylurea agents * current use of corticosteroids \> 5 days/month on average * current use of medications for treatment of psychosis or manic-depressive illness * use of weight-loss medications in previous 3 months * dependence on others for food procurement or preparation * ischemic changes on exercise treadmill test

Keywords: glucose insulin lipids c-reactive protein adiponectin leptin tnf alpha il-6 quality of life functional status
effect of ultrasound cavitation on insulin resistance in patients with central obesity in female

Conditions: Central Obesity

Summary: the purpose of this study was to investigate the effect of ultrasound cavitation on insulin resistance, hba1c and skin fold in patients with abdominal central obesity.

few researchers have detected the effects of ultrasonic cavitation on insulin resistance in subjects with central obesity. however, there were many conflicts and no clear evidence in the literature concerning the superiority of cavitation on body contour adjustment. consequently, this study aimed to investigate the effects of ultrasound cavitation, aerobic exercise and a low-calorie dietary program on insulin resistance and total plasma homa ir and body contouring in female with abdominal obesity.

Eligibility criteria:
inclusion criteria: * female subjects with central obesity. * female participants aged between 25 to 40 years. * body mass index (bmi) ranged from 30 to 35 kg/m2 as high bmi indicates more obesity and central obesity. * waist circumference greater than 88 cm, indicative of abdominal obesity. * diagnosed with insulin resistance (homa-ir \> 2.9). * sedentary lifestyle, defined as engaging in less than 150 minutes of moderate-intensity physical activity per week. * willingness to provide informed consent and comply with study procedures. exclusion criteria: * • subjects diagnosed with dm (hba1c more than 6.5%). * history of metabolic disorders such as type 1 diabetes or thyroid disorders. * subjects with bmi less than 30 kg/m2. * subjects diagnosed with heart disease, liver as well as kidney diseases. * subjects who take oral contraceptives. * subjects with gestational diabetes. * pregnant or breastfeeding women were excluded from the study. * use of weight-loss medications or supplements within the past six months. * previous surgical procedures for weight loss or body contouring. * contraindications to ultrasound therapy (e.g., metal implants in the abdomen, active skin infections). * participation in another clinical trial within the last three months.

Keywords: central obesity ultrasound cavitation insulin resistance homa ir
new pre-surgical scoring system for uterine septum

Conditions: Septate Uterus

Summary: comparing surgical outcomes of hysteroscopic metroplasty for uterine septum when using the standard esge or asrm classifications vs the novel scoring system dubbed shawki septum scoring system. outcomes based primarily on completion of the septal correction (no residual parts) and avoiding complications, the most significant of which are uterine perforation.


Eligibility criteria:
inclusion criteria: * uterine septum diagnosed by 3d ultrasound exclusion criteria: -

Keywords: hysterscopy congenital uterine anomaly uterine septum septet uterus novel scoring system shawki septum scoring system
strict versus permissive thresholds for initiation of pharmacotherapy in gestational diabetes (start 2)

Conditions: Gestational Diabetes; Pregnancy Related

Summary: the aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (gdm). our goal is to compare a strict and permissive threshold. the strict study arm target range will be 65-120 mg/dl, with time in range goal of 70%. the permissive study arm target range will be 65-140 mg/dl, with target time in range goal of 70%.

pregnancy is a state of insulin resistance to ensure that the growing fetus has ample nutrition. gestational diabetes (gdm) develops in pregnant patients with pancreatic dysfunction that leads to impairment of glucose tolerance. various studies have examined the benefit of treatment for gdm, including the 2005 australian carbohydrate intolerance study in pregnant women (achois) and the 2009 landon et al randomized controlled trials. these studies found that treatment was associated with a significant reduction in newborn complications of perinatal death, shoulder dystocia, large for gestational age infants, cesarean delivery, and birth trauma. the specific threshold value for initiation and up-titration of medical therapy is unknown. lack of evidence leads to a wide variation in clinical practice of pharmacological initiation and titration for gdm. a systematic review and meta-analysis by caissutti in 2019 analyzed criteria for initiating pharmacotherapy for gdm and noted the following: 12 of 15 trials initiated pharmacotherapy after 1-2 abnormal values over 1-2 weeks, 2 studies initiated pharmacotherapy after 50% of overall values were abnormal, and 1 study initiated pharmacotherapy after 30% of overall values were abnormal. however, there have been no randomized controlled trials of head-to-head comparison of different thresholds. the aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gdm using continuous glucose monitor. our goal is to compare a strict and permissive threshold. the strict study arm target range will be 65-120 mg/dl, with time in range goal of 70%. the permissive study arm target range will be 65-140 mg/dl, with target time in range goal of 70%.

Eligibility criteria:
inclusion criteria: * live, non-anomalous fetus * literacy in english, spanish, mandarin, or arabic * patients are also required to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol. exclusion criteria: * \<18 years at edd * pre-existing diabetes or diagnosis of gdm prior to 24 weeks * multi-fetal gestation * known major fetal anomaly * known allergy to insulin * chronic maternal corticosteroid use * diagnosis of gdm based on finger sticks alone * patients who have contraindication to oral glucose tolerance test * a primary language other than english, spanish, mandarin, or arabic

Keywords: gestational diabetes pregnancy insulin initiation of medication
an evaluation of a mind-body medicine training program for parole services division staff

Conditions: Healthy

Summary: the goal of this study is to evaluate the effectiveness of a mind-body medicine training program on parole services staff. the main questions it aims to answer are: * will participation in the training increase resilience; empathy; the belief that one can cope with difficult situations; and decrease symptoms of depression, stress, anxiety, and burnout? * what is the personal and professional impact of the training program? sixty staff members of the indiana department of correction parole services division will do the following: * attend an initial 4-day mind-body medicine training. mind-body techniques taught in the training include: meditation; a breathing exercise; biofeedback; guided imagery; expressing oneself through drawings and writing; movement to reduce stress; and family trees to explore family dynamics. * attend a 2-day practicum. the 2-day practicum will teach staff the ways in which they can share the skills they have learned one-on-one with parolees and families of parolees. * attend 4 biweekly sessions of 2-hour group consultation sessions. the consultations will support the use of the mind-body skills with the parolees. participants will also do the following: * fill out standardized questionnaires online before and after the training program in order to measure changes in resilience; empathy; the belief that one can cope with difficult situations; and symptoms of depression, stress, anxiety, and burnout. * fill out an additional online questionnaire three months after the consultation sessions to determine how trainees are using the mind-body skills in their work. * participate in an online group interview to determine how trainees are using the skills and how the training has affected them personally and professionally.


Eligibility criteria:
inclusion criteria for mind-body medicine training : * being a staff member of the division of parole services * english speaking * being 18 years of age or older * able to fully participate in the training and the small groups included in the training exclusion criteria for mind-body medicine training: • none: it is expected that all parole staff will be able to fully participate in the training and the small groups included in the training inclusion criteria for focus group participation : * completion of the mind-body medicine training * currently supervising parolees * teaching or using mind-body skills with their supervised parolees * being 18 years of age or older * english speaking. exclusion criteria for focus group participation: • none, as long as the trained staff meet the inclusion criteria.

Keywords: resilience empathy burnout stress meditation mind-body therapies
deep brain stimulation for treatment-resistant obsessive compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: this study will evaluate the use of deep brain stimulation (dbs) to reduce symptom severity and enhance the quality of life for patients with treatment-resistant obsessive compulsive disorder (ocd).

despite advances in pharmacological and behavioral therapies for ocd, a substantial number of patients fail to improve significantly following years of conventional and experimental interventions. for some patients, stereotactic neurosurgery is the only promising option available. although this procedure has relatively few side effects in the majority of ocd patients and may lead to enduring benefits, its effects on brain tissue and function are irreversible. bilateral deep brain stimulation (dbs) is an adjustable and partially reversible procedure that may be a more effective treatment for patients with ocd. this study will determine the effectiveness, safety, and tolerability of dbs in patients with treatment-refractory ocd. participants receive dbs treatment for 30 months. obsessive compulsive scales, depression scales, neuropsychological evaluations, and surveys are used to assess participants. participants are monitored for 2 years after dbs treatment.

Eligibility criteria:
inclusion criteria: * intractable, malignant, and treatment refractory ocd that has caused substantial suffering and a reduction in the patient's psychosocial functioning for \> 5 years * poor prognosis without neurosurgical intervention * failed an adequate trial of clomipramine and at least two of the following selective serotonin reuptake inhibitors (ssris): fluoxetine, fluvoxamine, citalopram, sertraline, and paroxetine. additionally, patients must have failed augmentation treatment with at least one of the above drugs for 1 month with at least two of the following: clonazepam, haloperidol, risperidone, olanzapine, and gabapentin. * willingness to undergo augmentation treatment with a low-dose neuroleptic if tics are present prior to surgery * failed an adequate trial of cognitive behavioral therapy/exposure response prevention while taking clomipramine and an ssri exclusion criteria: * current or lifetime axis i diagnosis that substantially complicates function, treatment, or the subject's ability to comply with study procedures, or may lead to serious adverse events such as overdose, attempted suicide, or other potentially threatening behaviors * diagnosis and/or treatment for depression within the past year. patients with a more distant history of depression will not be excluded. * previous neurosurgical procedure or axis iii diagnosis of brain pathology * implants that contain electrical circuitry, generate electrical signals, and/or have metal parts * nonremovable body jewelry * anticoagulants or other medications that would put patients at risk for surgery-related complications * diathermy for physical therapy * pregnancy
the relation between plasma irisin level and endothelial dysfunction in type 2 diabetes

Conditions: Irisin; Endothelial Dysfunction; Type 2 Diabetes

Summary: irisin is a signaling protein that is released into the blood from skeletal muscle after proteolysis of the membrane protein fndc5 . fndc5, encoded by the fndc5 gene. irisin activity on subcutaneous white adipose tissue, both in culture and in vivo, stimulated ucp1 expression and induction of brown adipocytes in white adipose tissue depots, a process known as white fat ''browning''. irisin increases total energy expenditure in animal models, and irisin expression in mice fed a high fat diet resulted in a significant improvement in glucose tolerance and a reduction in fasting insulin levels. collectively, these data suggest that decreased serum irisin levels may be associated with the development of insulin resistance and type 2 diabetes. indeed, some studies showed that irisin levels were decreased in newly diagnosed type 2 diabetes. endothelial dysfunction is an early physiological event in atherosclerosis. however, to date, no data are available on the relationship between circulating irisin and endothelial dysfunction in diabetes. therefore, the investigators hypothesized that circulating irisin level is associated with endothelial dysfunction.


Eligibility criteria:
inclusion criteria: * newly diagnosed type 2 diabetic patients * aged 40～70 years exclusion criteria: * patients with hypertension and those with micro- and macroangiopathy, including nephropathy \[urinary albumin excretion rate (uaer) \> 20 μg/min\], retinopathy (at least one microaneurysm or hemorrhage or exudates in either eye), neuropathy (pain in extremities, paresthesias, and absent tendon reﬂexes and/or absent vibration sense), coronary artery disease (myocardial infarction, ischemia electrocardiogram changes, and angina), cerebrovascular disease (transient ischemic attack or stroke), and peripheral vascular disease (the abolition of one or more peripheral arterial pulse and/or intermittent claudication and/or a past history of revascularization of the lower limbs) were excluded from the study.
study about predicting fluid responsiveness in children undergoing neurosurgery

Conditions: Fluid Responsiveness

Summary: the purpose of this study is to evaluate static and dynamic parameters, echocardiographic parameters, and pleth variability index for predicting fluid responsiveness in children. children who need volume expansion will receive colloid 10 ml/kg. blood pressure, heart rate, central venous pressure, systolic pressure variation, pulse pressure variation, delta down, aortic blood flow velocity variation, inferior vena cava diameter variation, and pleth variability index will be measure before and after volume expansion. patients will be classified as responders to volume loading if stoke volume index increase by at least 15%.


Eligibility criteria:
inclusion criteria: * neurosurgery under general anesthesia * \< 8 years old exclusion criteria: * cardiac disease * pulmonary, renal and hepatic disease * infectious disease * hematologic and muscular disease

Keywords: pulse pressure variation systolic pressure variation central venous pressure aortic blood flow velocity variation pleth variability index